SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
CIA-Linked Investor Helped Quantum Systems Expand in US 
France Targets Shein, Temu With Fast-Fashion Fees 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Add as a preferred source on Google
CARMIEL, Israel, March 15, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference on Friday, March 23, 2018 at 8:30 am Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York City.
A live and archived webcast of the presentation will be available at www.protalix.com, on the event calendar page.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has entered into an ex-United States partnership with Chiesi Farmaceutici S.p.A. for the development and commercialization of pegunigalsidase alfa. Protalix maintains full rights to pegunigalsidase alfa in the United States.
Investor Contact
Marcy Nanus, Managing Director
Solebury Trout Group
646-378-2927
[email protected]
